Influence of vitamin K antagonist treatment on activated partial thromboplastin time by MULLIEZ, SYLVIE et al.
Clin Chem Lab Med 2015; 53(2): e47–e50
Letter to the Editor
Sylvie M.N. Mulliez, Julie Van den Bogaert and Katrien M.J. Devreese*
Influence of vitamin K antagonist treatment on 
activated partial thromboplastin time
DOI 10.1515/cclm-2014-0688
Received July 4, 2014; accepted July 21, 2014; previously published 
online August 19, 2014
Keywords: activated partial thromboplastin time; inter-
national normalized ratio (INR); oral anticoagulant; pro-
thrombin time; vitamin K antagonist.
To the Editor,
Vitamin K antagonists (VKA) perform their anticoagu-
lant effect by inhibiting vitamin K epoxide reductase, an 
enzyme that recycles oxidized vitamin K to its reduced 
form. Vitamin K is a cofactor for the post-translational 
carboxylation of several vitamin K-dependent proteins. 
Consequently, VKA result in defective synthesis of the 
vitamin K-dependent clotting factors: factor (F) II, VII, 
IX, and X. The recommended method used for monitor-
ing VKA is determination of the international normalized 
ratio (INR) which is derived from the prothrombin time 
(PT) [1]. This test is sensitive to the levels of FII, FVII and 
FX, but is not responsive to reduction of FIX, which can be 
detected by activated partial thromboplastin time (aPTT). 
APTT measures the efficacy of both the intrinsic and the 
common coagulation pathway and is also influenced by 
vitamin K-dependent clotting factors (FIX, FX and FII). 
Therefore, among patients treated with VKA, a prolonged 
aPTT is observed. The relationship between an elevated 
INR in a patient on VKA treatment with the aPTT is not 
known and probably depends on the FIX level. Very low 
FIX in patients on VKA treatment, due to mutation in the 
FIX gene, with prolonged aPTT have been described, but 
is very rare [2]. This relationship likely depends also on 
the combination of aPTT reagent and instrument utilized 
and aPTT reagents differ largely in sensitivity to coagula-
tion factor deficiency [3]. Although aPTT measurement 
is not indicated in VKA monitoring, the aPTT is widely 
used as part of a coagulation screening panel. In case of 
VKA-treated patients a prolonged aPTT is often due to 
the VKA, although the measure of prolongation of aPTT 
in VKA-treated patients is unknown. Misinterpretation 
of a prolonged aPTT should be avoided and therefore the 
sensitivity of the aPTT reagent towards INR in AVK-treated 
patients can be informative.
In this study, we have evaluated the relationship 
between INR and aPTT in patients on VKA anticoagu-
lant treatment and the sensitivity of three different aPTT 
reagents, PTT-A (Diagnostica Stago, Asnières-sur-Seine, 
France), Cephascreen® (Diagnostica Stago) and C.K. 
Prest® (Diagnostica Stago).
Patients from the Ghent University Hospital treated 
with VKA and monitored by PT/INR were collected. The 
study was approved by the Belgian regulatory agency 
(B670201419819). The trial was conducted in accordance 
with the Declaration of Helsinki and approved by the 
Ethics Committee of Ghent University Hospital (registra-
tion no. 2014/101). Samples with an INR  > 1.5 were pro-
spectively and consecutively collected from January to 
April 2014 and frozen at –20 °C in different aliquots within 
4 h after sampling. The aPTT with three different reagents 
(PTT-A, C.K. Prest® and Cephascreen®) and PT/INR (Neo-
plastine® CI plus, Diagnostica Stago) were measured. 
A simple linear regression analysis with 95% and 90% 
prediction limits between aPTT and INR was made using 
SPPS® Statistics 20 (IBM Business Analytics, Armonk, NY, 
USA). Samples with disproportionate aPTT (‘outliers’) 
were identified as those with an aPTT outside 90% predic-
tion limits and were further analyzed. To measure clotting 
factor activity the one-stage clotting assay was used. STA®-
Thrombin 2 (Diagnostica Stago) and Biophen Heparin LRT 
(Hyphen BioMed, Andresy, France) were used to measure, 
respectively, thrombin time (TT) and anti-Xa activity. 
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Lupus anticoagulant (LA) was detected according to the 
SSC guidelines using the dilute Russell’s Viper Venom 
Test (dRVVT) (LA screen and LA confirm, Life Diagnostics, 
DSRV, Clarkstons, MI, USA) and a sensitive aPTT assay 
(PTT-LA and Staclot® LA, Diagnostica Stago) [4]. C-reac-
tive protein (CRP) was measured on Cobas®8000 (Roche 
Diagnostics, Belgium).
Seven hundred samples were collected. In a first step 
the aPTT with the three different reagents and PT/INR 
were measured (Figure 1). A Grubb’s outlier test (α = 0.05) 
on bias between INR measured during the study and 
the routinely measured INR was performed to exclude 
samples (n = 45) influenced by the freezing/thawing cycle. 
Linear regression analysis between aPTT and INR (n = 655) 
was performed. Samples of patients with disproportionate 
aPTT were identified by using the 95% and 90% predic-
tion limits (Figure 2). In total 55 outliers were identified, 
five samples with a disproportionate short aPTT and 50 
with a disproportionate prolonged aPTT for correspond-
ing INR. In Table 1 the mean aPTT of all samples within 
the prediction limits and the upper limit of aPTT was cal-
culated for the three aPTT reagents for INR of 2, 3 and 4.
Next, we further analyzed the samples beyond the 
90% prediction limit with at least one of the aPTT reagents. 
Samples with a disproportional short aPTT (n = 5) were 
examined for FVIII and FIX activity. In four out of the five 
samples the elevated FVIII level  > 150% (normal range, 
60%–150%) could explain the disproportional short 
aPTT. One sample showed a normal FVIII activity of 103% 
and the FIX activity was low (23.3%) and thus could not 
explain the disproportion. FII, FX and FVII were, respec-
tively, 46%, 28%, and 2%. FVII influences strongly the 
PT-INR [5]. The discrepancy between the relatively high 
FII and FX level and very low FVII level could explain the 
disproportional low aPTT (respectively, 67.4 s, 48.8 s, and 
63.4 s with PTT-A, C.K. Prest® and Cephascreen®) for high 
INR of 14.1.
Samples with disproportional prolonged aPTT (n = 50) 
were further analyzed for TT and anti-Xa activity to rule 
out the presence of heparin (UFH) or low molecular weight 
heparin (LMWH). In 37 out of 50 samples (74%) presence 
of UFH or LMWH was confirmed. We explored the remain-
ing 13 out of 50 samples by consulting the medical and 
laboratory history of these patients and extra analyses. 
Five out of 13 samples showed the presence of LA. LA 
interferes with clotting in phospholipid dependent clot-
ting tests, such as aPTT and explains the prolonged aPTT 
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Figure 1 Flowchart of the selection of the samples and the results.
aPTT, activated partial thromboplastin time; CRP, C reactive protein; F, factor; INR, international normalized ratio; LA, lupus anticoagulant; 
LMWH, low molecular weight heparin; PT, prothrombin time; UFH, unfractioned heparin.
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(Table 2). CRP interacts with phospholipids and results 
in an in vitro prolongation of phospholipid-dependent 
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Figure 2 APTT values in relation to INR for 655 samples.
APTT measured with three different reagents, respectively, PTT-A (A, B), C.K. Prest®(C, D) and CEPHASCREEN® (E, F). The linear regres-
sion analysis revealed the following relation between INR and aPTT: aPTT (PTT-A) = 35.4+7.1 INR, aPTT (C.K. Prest®) = 30.6+4.3 INR and aPTT 
(CEPHASCREEN®) = 29.4+6.9 INR. The lines indicate the linear regression line and the upper and lower 90% and 95%, respectively, in A, B, C 
and D, E and F, prediction limits of the linear regression between the aPTT and INR.
Table 1 Mean aPTT for three different aPTT reagents (PTT-A, C.K. 
Prest® and Cephascreen®) excluding 5% and 10% of the data, with 
disproportionate prolonged and shortened aPTT and the upper limit 
of the expected aPTT with the 95% and 90% prediction limits of the 
linear regression analysis for INR of 2, 3 and 4.










PTT-A   2  46.9  46.8   < 79.1   < 74.6
  3  54.8  54.2   < 86.1   < 81.7
  4  62.7  61.6   < 93.2   < 88.7
C.K. Prest®   2  37.6  37.5   < 60.3   < 56.6
  3  41.9  41.7   < 64.6   < 60.8
  4  46.2  45.9   < 68.9   < 65.1
Cephascreen®  2  40.8  40.8   < 76.4   < 71.7
  3  47.8  47.6   < 83.3   < 78.6
  4  54.8  54.5   < 90.2   < 85.5
aPTT, activated partial thromboplastin time; PL, prediction limit; PT, 
prothrombin time.
coagulation tests by LA due to interference with accumu-
lation of coagulation factors on negatively charged phos-
pholipids [6, 7]. The influence is reagent dependent as 
observed in the present data and explains the dispropor-
tional prolonged aPTT with Cephascreen® and PTT-A, 
reagents sensitive to high CRP concentration and not with 
C.K. Prest®, a reagent insensitive for CRP interference [7]. 
Furthermore, we found one sample with a factor FXII 
deficiency.
For three out of the 13 samples we could not iden-
tify a cause for the disproportional prolonged aPTT (CRP 
Table 2 INR and aPTT with three different reagents (PTT-A, C.K. 
Prest® and Cephascreen®) of four samples with CRP  > 180 mg/L.
INR  aPTT 
PTT-A, s






4.3  99.9  56.3  91.8  184.4
6.2  101.2  62.8  105.8  332.4
11.4  154.9  82.7  139.4  405.9
12.8  155.7  83.1  145.8   > 400
aPTT, activated partial thromboplastin time; CRP, C reactive protein; 
INR, international normalized ration.
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level, respectively, 5, 8 and 42 mg/L). One of these samples 
showed a FIX activity of only 7.6% for an INR of 3.8. As 
described by Legnani et  al. vitamin K antagonist can 
greatly influence the factor IX activity but the sensitivity 
of factor IX activity to VKA varies greatly between indi-
viduals with a similar anticoagulation intensity level as 
measured by INR [2]. See Supplemental Data, Table 1, for 
an overview of the aPTT values and INR of the 55 samples 
with disproportional short and prolonged aPTT and indi-
cation of the cause.
In conclusion, the rate of aPTT prolongation in VKA-
treated patients is reagent dependent. We calculated the 
expected prolongation of aPTT with three different rea-
gents (PTT-A, C.K. Prest® and Cephascreen®) for INR of 
2, 3 and 4. An extensively prolonged aPTT in VKA-treated 
patients may not be due to VKA alone. Disproportional 
prolonged aPTT in patients on VKA treatment merit 
further attention and should be investigated to avoid mis-
interpretation. In 47 of the 50 samples (94%) we found 
another cause resulting in a prolonged aPTT: presence 
of UFH/LMWH (n = 37), LA (n = 5) high CRP (n = 4) and FXII 
deficiency (n = 1).
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